Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Syndax Pharmaceuticals Inc (SNDX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 SC 13G/A Frazier Life Sciences Public Fund, L.P. reports a 0% stake in Syndax Pharmaceuticals, Inc.
10/02/2023 8-K Quarterly results
08/09/2023 144 Form 144 - Report of proposed sale of securities:
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update – Announced positive topline results from the pivotal AGAVE-201 trial of axatilimab in cGVHD – – Topline data from the pivotal AUGMENT-101 trial of revumenib in KMT2Ar acute leukemia on track for the third quarter of 2023 – – Two U.S. registrational filings expected by the end of 2023 – – Company to host conference call today at 4:30 p.m. ET –"
08/02/2023 144 Form 144 - Report of proposed sale of securities:
07/24/2023 8-K Quarterly results
07/10/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 144 Form 144 - Report of proposed sale of securities:
05/26/2023 8-K Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive ...
Docs: "SYNDAX PHARMACEUTICALS, INC. common Stock SALES AGREEMENT",
"Building D, Floor 3"
05/26/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/09/2023 144 Form 144 - Report of proposed sale of securities:
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update – Topline data from the pivotal AGAVE-201 trial of axatilimab in cGVHD on track for mid-2023 – – Topline data from the pivotal AUGMENT-101 trial of revumenib in KMT2Ar acute leukemia on track for the third quarter of 2023 – – Two U.S. registrational filings expected by the end of 2023 – – Company to host conference call today at 4:30 p.m. ET –"
04/18/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/30/2023 8-K Quarterly results
03/28/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
02/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/28/2023 10-K Annual Report for the period ended December 31, 2022
02/28/2023 8-K Quarterly results
Docs: "Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update – Topline data from AUGMENT-101 KMT2Ar patients expected in the third quarter of 2023 – – Topline data from the pivotal AGAVE-201 trial on track for mid-2023 – – Two U.S. registrational filings expected by the end of 2023 – – Company to host conference call today at 4:30 p.m. ET –"
02/14/2023 SC 13G/A Nantahala Capital Management, LLC reports a 1.4% stake in Syndax Pharmaceuticals, Inc.
02/14/2023 SC 13G/A Avidity Partners Management LP reports a 9.7% stake in Syndax Pharmaceuticals, Inc.
02/14/2023 SC 13G/A Frazier Life Sciences Public Fund, L.P. reports a 5.4% stake in Syndax Pharmaceuticals, Inc.
02/14/2023 SC 13G/A BIOTECHNOLOGY VALUE FUND L P reports a 2.1% stake in Syndax Pharmaceuticals, Inc.
02/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SYNDAX PHARMACEUTICALS, INC. 2023 INDUCEMENT PLAN Syndax Pharmaceuticals, Inc., a Delaware corporation , sets forth herein the terms of its 2023 Inducement Plan , as follows: 1. GENERAL 1.1 Purpose. This Plan is intended to provide an inducement material for certain individuals to enter into employment with the Company within the meaning of Rule 5635 of the NASDAQ Marketplace Rules, and incentives to Eligible Employees to stimulate their efforts towards the success of the Company and to operate and manage its business in a manner that will provide for the long-term growth and profitability of the Company. To that end, the Plan provides for the grant of Awards of Options, Stock Appreciation Rights, Restricted Stock, Unrestricted Stock, Stock Units, Dividend Equivalent Rights, Performance Aw...",
"Non-qualified Option This Agreement evidences an award of an Option exercisable for that number of shares of Stock set forth on the cover sheet and subject to the vesting and other conditions set forth in the Agreement and in the Plan. This Option is granted subject to the terms and conditions of the Plan as a material inducement to you entering into employment with the Company in compliance with NASDAQ Listing Rule 5634. This Option is not intended to be an incentive stock option under Section 422 of the Code and will be interpreted accordingly. Transfer of Option During your lifetime, only you may exercise the Option. The Option may not be sold, assigned, transferred, pledged, hypothecated or otherwise encumbered, whether by operation of law or otherwise, nor may the Option be made subje..."
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/10/2023 SC 13G WELLINGTON MANAGEMENT GROUP LLP reports a 11.7% stake in Syndax Pharmaceuticals Inc
12/14/2022 8-K Quarterly results
12/07/2022 8-K Quarterly results
12/07/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/06/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/05/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy